Glucagon and GLP-1 receptor co-agonist
Cotadutide 300 ug subcutaneous once daily
COTA_SC_300UG_QD
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Placebo | MD -0.70 (-1.18 to -0.19) | 0.35 |
| Type 2 diabetes (adults) | HbA1c change | weeks 36 to 64 (target week 52) | Placebo | MD -0.56 (-0.86 to -0.27) | 0.78 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 36 to 64 (target week 52) | Placebo | MD -3.06 (-4.84 to -0.98) | 0.72 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 20 to 36 (target week 26) | Placebo | MD -3.03 (-4.66 to -1.39) | 0.85 |
| Type 2 diabetes (adults) | HbA1c below 7 percent | weeks 20 to 36 (target week 26) | Placebo | OR 4.13 (1.65 to 9.27) | 0.52 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.53 (0.01 to 39.30) | 0.45 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 2.57 (0.30 to 29.62) | 0.28 |
| Type 2 diabetes (adults) | Percent body weight change | weeks 20 to 40 (target week 26) | Placebo | MD -3.26 (-7.86 to 2.71) | 0.69 |
| Type 2 diabetes (adults) | Percent body weight change | weeks 40 to 104 (target week 68) | Placebo | MD -2.79 (-8.73 to 4.74) | 0.75 |
| Type 2 diabetes (adults) | Weight loss of 5 percent or more | weeks 40 to 104 (target week 68) | Placebo | OR 5.59 (1.51 to 14.81) | 0.76 |
| Type 2 diabetes (adults) | Weight loss of 5 percent or more | weeks 20 to 40 (target week 26) | Placebo | OR 6.22 (1.85 to 16.82) | 0.69 |
| Type 2 diabetes (adults) | Weight loss of 10 percent or more | weeks 20 to 40 (target week 26) | Placebo | OR 6.60 (1.40 to 36.11) | 0.58 |
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 0.77 (0.42 to 1.45) | 0.61 |
| Type 2 diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 8.19 (3.73 to 18.71) | 0.09 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 7.33 (4.44 to 12.36) | 0.13 |
| Type 2 diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 7.49 (3.72 to 16.11) | 0.19 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 2.88 (1.53 to 5.57) | 0.25 |
| Type 2 diabetes (adults) | Constipation | longest follow-up | Placebo | HR 3.49 (1.39 to 9.92) | 0.22 |
| Chronic kidney disease with diabetes | Serious adverse events | longest follow-up | Placebo | HR 0.96 (0.11 to 8.41) | 0.60 |
| Chronic kidney disease with diabetes | Discontinuation due to adverse events | longest follow-up | Placebo | HR 1.75 (0.18 to 20.43) | 0.54 |
| Chronic kidney disease with diabetes | Nausea | longest follow-up | Placebo | HR 2.48 (0.54 to 11.83) | 0.51 |
| Chronic kidney disease with diabetes | Vomiting | longest follow-up | Placebo | HR 5.31 (0.76 to 50.86) | 0.37 |
| Chronic kidney disease with diabetes | Diarrhea | longest follow-up | Placebo | HR 13.96 (1.18 to 384) | 0.11 |
Trials
- NCT03555994An Exploratory Phase 2, Randomised, Double-blind, Placebo-controlled, and Open-label Active Comparator Study to Evaluate the Effect of MEDI0382 on Hepatic Glycogen Metabolism in Overweight and Obese Subjects With Type 2 Diabetes Mellitus.2018 · 51 randomized · 5 weeks
- NCT03550378A Phase 2a, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of MEDI0382 in Subjects With Type 2 Diabetes Mellitus and Renal Impairment2018 · 41 randomized · 4.57 weeks
- NCT03235050A Phase IIb, Randomised, Parallel, Double-Blind Placebo-Controlled and Open-Label Active Comparator Study to Evaluate the Efficacy and Safety of MEDI0382 in the Treatment of Overweight and Obese Subjects With Type 2 Diabetes Mellitus2017 · 834 randomized · 54 weeks